Prostate Cell News Volume 7.17 | May 13 2016

Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Scientists analytically validated an RISH assay for total AR and AR-V7 for use in formalin fixed paraffin embedded prostate tumors. [Clin Cancer Res] Abstract

The Transcription Factor FOXF1 Promotes Prostate Cancer by Stimulating the Mitogen-Activated Protein Kinase ERK5
The authors detected a population of forkhead box (FOX) F1-positive tumor cells in aggressive mouse and human prostate adenocarcinoma (PCa). Using two murine orthotopic models of PCa, they found that overexpression of FOXF1 in Myc-CaP and TRAMP prostate tumor cells induced tumor growth in the prostate and progression to peritoneal metastasis. [Sci Signal] Abstract

Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison with PTEN FISH
PTEN loss is a promising prognostic and predictive biomarker in prostate cancer. Because it occurs most commonly via PTEN gene deletion, researchers developed a clinical-grade, automated, and inexpensive immunohistochemical assay to detect PTEN loss. [Mod Pathol] Abstract

Regulation of Prostate Development and Benign Prostatic Hyperplasia by Autocrine Cholinergic Signaling via Maintaining the Epithelial Progenitor Cells in Proliferating Status
Researchers report that autocrine cholinergic signaling promoted the proliferation and inhibited the differentiation of prostate epithelial progenitor cells in organotypic cultures. These results were confirmed by ex vivo lineage tracing assays and in vivo renal capsule recombination assays. [Stem Cell Rep] Full Article

GPR30 Promotes Prostate Stromal Cell Activation via Suppression of ERα Expression and Its Downstream Signaling Pathway
Researchers aimed to investigate the possible origin of prostate cancer-associated fibroblasts and the effects of estrogen receptors GPR30 and ERα on stromal cell activation. [Endocrinology] Abstract | Full Article

MUC1 Is Upregulated in Advanced Prostate Cancer and Is an Independent Prognostic Factor
MUC1 expression was evaluated in tissue microarrays constructed from 119 nodal positive prostate cancer patients treated by radical prostatectomy and extended lymphadenectomy. MUC1 status was correlated with various tumor features and biochemical recurrence-free, disease-specific survival and overall survival. [Prostate Cancer Prostatic Dis] Abstract

Rap2B Promotes Cell Proliferation, Migration and Invasion in Prostate Cancer
Scientists elucidated the stimulative role of Rap2B in prostate cancer cell proliferation, migration and invasion by means of the CCK-8 cell proliferation assay, cell cycle analysis and transwell migration assay. [Med Oncol] Abstract

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Scientists revealed genomic characteristics from cell-free DNA associated with clinical outcomes during enzalutamide treatment. [JAMA Oncol] Abstract

CLINICAL RESEARCH

Salvage Radiotherapy with or without Short-Term Hormone Therapy for Rising Prostate-Specific Antigen Concentration after Radical Prostatectomy (GETUG-AFU 16): A Randomized, Multicenter, Open-Label Phase III Trial
Scientists aimed to establish the effect of adding short-term androgen suppression at the time of salvage radiotherapy on biochemical outcome and overall survival in men with rising prostate-specific antigen following radical prostatectomy. [Lancet Oncol] Abstract

Timing of Androgen-Deprivation Therapy in Patients with Prostate Cancer with a Rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a Randomized, Multicenter, Non-Blinded, Phase III Trial
Investigators aimed to assess whether immediate androgen-deprivation therapy improves overall survival compared with delayed therapy. [Lancet Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

GenomeDx’s Decipher Platform Identifies Gene Expression Associated with Resistance to Chemotherapy Treatment in Bladder Cancer
GenomeDx Biosciences announced that its Decipher^® platform was used to evaluate molecular subtypes associated with resistance to platinum-based neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer, supporting the potential use of a genomic signature to guide patient therapy. [Press release from GenomeDx Biosciences discussing research presented at the American Urological Association (AUA) 111^th Annual Scientific Meeting, San Diego] Press Release

GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor
GTx, Inc. announced the first public presentation of preclinical data from the company’s selective androgen receptor (AR) degrader (SARD) program. The results demonstrate that the company’s highly potent SARDs selectively bind to the ligand binding domain and interact with the N-terminal domain of the androgen receptor and inhibit and degrade the AR at very low concentrations. [Press release from GTx, Inc. discussing research presented at the American Urological Association (AUA) 111^th Annual Scientific Meeting, San Diego] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells. Watch the video.

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer
Hutchison China MediTech Limited announced that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or metastatic colorectal cancer (CRC) in China, where an estimated 390,000 new cases of CRC were diagnosed in 2012. [Hutchison China MediTech Limited] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Senior Scientist – Protein Analytics of Prostate and Other Cancer (Exosome Diagnostics)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cancer Genomics (Henry Jackson Foundation)

Postdoctoral Fellow – Mechanisms of Castrate Resistance (University of Chicago)

Postdoctoral Research Fellow – Molecular Epidemiology of Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Genetic Determinants of Cancer (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

Lead Scientist – Prostate Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellowship – Castration Resistant Prostate Cancer (University of Florida)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.